Depression

A systemic review has concluded cognitive behavioral therapy does not need to be conducted in person to be effective. The study found the therapy was as effective when administered using video conferencing and email tools, as face-to-face sessions.

A new pilot study has demonstrated nitrous oxide, commonly known as laughing gas, may help military veterans suffering from PTSD. A larger trial is now underway after several studies demonstrated potential new uses for the gas.

A new study has solved a long-standing mystery of how acute stress seems to amplify inflammatory disease, despite the fact many stress hormones actually suppress the immune system. It found a specific immune cell is released by fat cells when stressed.

Scientists have discovered a new mechanism to help illustrate the rapid antidepressant qualities of ketamine. Imaging patients with depression revealed ketamine’s effects are a result of its interaction with a particular kind of serotonin receptor.

Stanford researchers optimized an FDA-approved form of non-invasive magnetic brain stimulation to better treat treatment-resistant depression. A preliminary study achieved a 90-percent remission rate, with larger trials underway.

Scientists at the University of Copenhagen have discovered a new substance that could alleviate the side effects of strong antidepressants, paving the way for safer forms of treatment that can be tolerated by more sufferers of the illness.

Following on from prior research finding brain wave patterns can signal whether antidepressant medication will be effective, a study is reporting the development of an algorithm that can predict patient response to antidepressants based on EEG data.

A new study is offering the first long-term insights into the efficacy of a single dose of psilocybin, in conjunction with psychotherapy, in treating depression and anxiety in patients with life-threatening cancer.

The US Food and Drug Administration (FDA) has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

Scientists at UC Berkeley have homed in on exactly which phase of sleep seems to best keep anxiety levels in check. The research suggests sleep deprivation lowers activity in the prefrontal cortex, a brain region that helps regulate our emotions.

A new metastudy is suggesting anti-inflammatory drugs can reduce symptoms of depression, affirming the long-suspected link between neuroinflammation and depression. However, another study is claiming there is no causal link between the two factors.

The results of a randomized controlled trial found dietary improvements lasting just a few weeks can improve overall mood and symptoms of anxiety.